Sean Laaman
Stock Analyst at Morgan Stanley
(2.90)
# 1,602
Out of 4,908 analysts
6
Total ratings
80%
Success rate
21.35%
Average return
Main Sectors:
Stocks Rated by Sean Laaman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXSM Axsome Therapeutics | Assumes: Overweight | $190 | $102.55 | +85.28% | 1 | Jul 3, 2025 | |
| IRON Disc Medicine | Assumes: Overweight | $85 | $60.75 | +39.92% | 1 | Jul 3, 2025 | |
| CERT Certara | Assumes: Equal-Weight | $16 | $10.62 | +50.66% | 1 | Jul 3, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $313 → $330 | $295.59 | +11.64% | 1 | Jun 27, 2025 | |
| ALEC Alector | Assumes: Underweight | $3 → $1.5 | $1.72 | -12.79% | 1 | Mar 7, 2025 | |
| RMD ResMed | Upgrades: Overweight | $169 | $267.40 | -36.80% | 1 | Oct 27, 2023 |
Axsome Therapeutics
Jul 3, 2025
Assumes: Overweight
Price Target: $190
Current: $102.55
Upside: +85.28%
Disc Medicine
Jul 3, 2025
Assumes: Overweight
Price Target: $85
Current: $60.75
Upside: +39.92%
Certara
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $16
Current: $10.62
Upside: +50.66%
BeOne Medicines
Jun 27, 2025
Maintains: Overweight
Price Target: $313 → $330
Current: $295.59
Upside: +11.64%
Alector
Mar 7, 2025
Assumes: Underweight
Price Target: $3 → $1.5
Current: $1.72
Upside: -12.79%
ResMed
Oct 27, 2023
Upgrades: Overweight
Price Target: $169
Current: $267.40
Upside: -36.80%